… Sec on TCE exposure as presumed connection to Parkinson's.pdf …

… Phase IIa study evaluating the metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, called … said Chris Maggos, who handles business development and communication at Addex. According to a recent article in … continues to acknowledge that mGluR4 is an exciting target for PD, it has decided to instead focus its resources on …

… the Wall Street Journal’s Informed Patient column discussed how patients living with movement disorders, including … As noted in the article, studies have shown that only 40% to 60% of PD patients ever seek care from a specialist. And … by 2030, awareness for these types of physicians is becoming crucial. In fact, a survey conducted by Harris Poll …

… challenge spurring existing and new donors at every level to give, or increase giving, to The Michael J. Fox … Ms. Wojcicki is co-founder of 23andMe, a personal genetics company. About The Michael J. Fox Foundation for Parkinson’s … pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement …

… We speak to patients about clinical research participation in our … . The Michael J. Fox Foundation also talks to doctors about how they discuss research with their patients and to … on how to engage with potential participants. The article recommends that researchers: Involve patients: Convene a …

… The latest clue to early detection of Parkinson's disease may lie … Neurology found that people with early-stage Parkinson's show a thinning of their retinas, a layer of light-sensitive … stages, learn more about its causes, and test therapies to stop its progression. The Michael J. Fox Foundation has …